Anti-IgE and chemotherapy: A critical appraisal of treatment options for severe asthma

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 5, 2007, Pages 585-592

  Walters, E Haydn ^a,b   Walters, Julia A E ^a   Wood Baker, Richard ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

^b ROYAL HOBART HOSPITAL   (Australia)

Author keywords

Anti IgE; Asthma; Immunoglobulin E; Omalizumab

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 4; LEUKOTRIENE D4; OMALIZUMAB; PLACEBO; THEOPHYLLINE; ANTI-IGE; ANTIASTHMATIC AGENT; ANTIIDIOTYPIC ANTIBODY; IMMUNOGLOBULIN E ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ALLERGIC REACTION; ASTHMA; ATOPY; CLINICAL PRACTICE; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; ECZEMA; EOSINOPHIL; HAY FEVER; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INJECTION SITE REACTION; META ANALYSIS; NASAL BIOPSY; PATHOPHYSIOLOGY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHINITIS; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ECONOMICS; EXPERT WITNESS; HYPERSENSITIVITY; IMMUNOLOGY; PHYSIOLOGY;

ADRENAL CORTEX HORMONES; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ASTHMA; EXPERT TESTIMONY; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; RANDOMIZED CONTROLLED TRIALS;

EID: 34047216952     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.5.585     Document Type: Review

References (49)

1. SUTTON BJ, GOULD HJ: The human IgE network. Nature (1993) 366:421-428.
2. PLATTS-MILLS TA: The role of immunoglobulin E in allergy and asthma. Am. J. Respir. Crit. Care. Med (2001) 164:S1-S5.
3. JENKINS MA, HOPPER JL, BOWES G et al.: Factors in childhood as predictors of asthma in adult life. Br. Med. J. (1994) 309:90-93.
4. BEASLEY R, CRANE J, LAI CK et al.: Prevalence and etiology of asthma. J. Allergy. Clin. Immunol. (2000) 105:5466-5472.
5. PEARCE N, PEKKNEN J, BEASLEY R: How much asthma is really attributable to atopy? Thorax (1999) 54:268-272.
6. BURROWS B, MARTINEZ FD, HALONEN M, BARBEE RA, CLINE MG: Association of asthma with serum IgE levels and skin-test reactivity to allergens. N. Engl. J. Med. (1989) 320:271-277.
7. MATHESON MC, ABRAMSON MJ, DHARMAGE SC et al.: Changes in indoor allergen and fungal levels predict changes in asthma activity among young adults. Clin. Exp. Allergy (2005) 35:907-913.
8. JENKINS MA, HOPPER JL, FLANDER LB et al.: The associations between childhood asthma and atopy, and parental asthma, hay fever and smoking. Paediatr. Perinat. Epidemiol. (1993) 7:67-76.
9. MARKS GB, MIHRISHAHI S, KEMP AS et al.: Prevention of asthma during the first 5 years of life: a randomised controlled study. J. Allergy. Clin. Immunol. (2006) 118:53-61.
10. WOODCOCK A, LOWE LA, MURRAY CS et al.: Early life environmental control: effect on symptoms, sensitization, and lung function at age 3 years. Am. J. Respir. Crit. Care. Med. (2004) 170:433-439.
11. UPHAM JW, HOLT PG: Environment and development of atopy. Curr. Opin. Allergy. Immunol. (2005) 5:167-122.
12. SPERGEL JM, PALLER AS: Atopic dermatitis and the atopic march. J. Allergy. Clin. Immunol. (2003) 112:S118-S127.
13. MACGLASHON DW, BOCHNER BS, ADELMAN DC et al.: Serum IgE level drives basophil and mast cell IgE receptor display. Int. Arch. Allergy. Immunol. (1997) 113:45-47.
14. MACGLASHON D, LICHTENSTEIN LM, MCKENZIE-WHITE J et al.: Upregulation of FcεRI on human basophils by IgE antibody is mediated by interaction of IgE with FcεRI. J. Allergy. Clin. Immunol. (1999) 104:492-498.
15. DJUKANOVIC R, WILSON S, KRAFT M et al.: Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic disease. Am. J. Respir. Crit. Care. Med. (2004) 170:583-593.
16. PRUSSIN C, GRIFFITH DT, BOESEL KM et al.: Omalizumab treatment downregulates dendritic cell FCERI expression. J. Allergy. Clin. Immunol. (2003) 112:1147-1154.
17. FAHY JV, FLEMMING HE, WONG HH et al.: The effect of an anti-IgE monoclonal antibody on the early- and the late-responses to allergen inhalation in asthmatic subjects. Am. J. Respir. Crit. Care. Med. (1997) 155:1828-1834.
18. BOULET LP, CHAPMAN KR, COTE J et al.: Inhibitory effects of an anti-IgE antibody E25 on allergen induced early asthmatic response. Am. J. Respir. Crit. Care. Med. (1997) 155:1835-1840.
19. FAHY JV, COCHROFT DW, BOULET LP et al.: Effect of aerosolized anti-IgE [E25] on airways responses to inhaled allergen in asthmatic subjects. Am. J. Respir. Crit. Care. Med. (1999) 160:1023-1027.
20. BRUNO L, PRIETO L, GUTIERREZ V et al.: Effect of omalizumab on adenosine 5′-monophosphate responsiveness in allergic asthma. XIX World Allergy Organization Congress. Munich, Germany (June 26 - July 1 2005). Abstr. 306.
21. WALKER S, MONTEIL M, PHELAN K et al.: Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst. Rev. (2006) 2:CD003559.
22. BUSSE W, CORREN J, LANIER BQ et al.: Anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J. Allergy. Clin. Immunol. (2001) 108:184-190.
23. HOLGATE ST, CHUCHALIN AG, HEBERT J et al.: Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin. Exp. Allergy (2004) 34:632-638.
24. HUMBERT M, BEASLEY R, AYRES J et al.: Benefits of omalizumab as add-on therapy in patients with severe asthma who are inadequately controlled despite best available therapy (Gina 2002 step 4 treatment): INNOVATE. Allergy (2005) 60:309-316.
25. MILGROM H, BERGER W, NAYAK A et al.: Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics (2001) 108:E36.
26. MILGROM H, FICK RB, SU J et al.: Treatment of allergic asthma with monoclonal anti-IgE antibody. N. Engl. J. Med. (1999) 341:1966-1973.
27. VIGNOLA AM, HUMBERT M, BOUSQUET J et al.: Efficacy and tolerability of anti-immunoglbulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy (2004) 59:709-717.
28. SOLER M, MATZ J, TOWNLEY R et al.: The anti-IgE antibody omalizumab reduces exacerbations and steroid requirements in allergic asthmatics. Eur. Respir. J. (2001) 18:254-261.
29. QURESHI F, PESTIAN J, DAVIS P et al.: Effect of nebulised ipratropium on the hospitalization rates of children with asthma. N. Engl. J. Med. (1998) 339:1030-1035.
30. WIJNHOVEN HAH, KRIEGSMAN DMW, HESSELINK AE et al.: Determinants of different dimensions of disease severity in asthma and COPD: Pulmonary function and quality of life. Chest (2001) 119:1034-1042.
31. CORREN J, CASALE T, DENIZ Y et al.: Omalizumab, a recombinant humanized anti-IgE antibody, reduced asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J. Allergy. Clin. Immunol. (2003) 111:87-90.
32. BABU KS, ARSHAD SH, HOLGATE ST: Anti-IgE treatment: an update. Allergy (2001) 56:1121-1128.
33. HOLGATE S, BOUSQUET J, WENZEL S et al.: Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients at high risk of serious asthma-related morbidity and mortality. Curr. Med. Res. Opin. (2001) 17:233-240.
34. BOUSQUET J, WENZEL S, HOLGATE S et al.: Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest (2004) 125:1378-1386.
35. BOUSQUET J, CABRERA P, BERKMAN N et al.: The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy (2005) 60:302-308.
36. HOLGATE ST, DJUKANOVIC R, CASALE T, BOUSQUET J: Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin. Exp. Allergy (2005) 35:408-416.
37. NOWAK D: Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab. Respiratory Medicine (2006) 100:1907-1917.
38. NHLBI/WHO: Workshop. Global Initiative on Asthma (GINA): management and prevention. Second Edition. NIH Publication. Washington (2002)
39. BARNES PJ, WOOLCOCK AJ: Difficult asthma. Eur. Respir. J. (1998) 12:1209-1218.
40. BATEMAN ED, BOUSHEY HA, BOUSQUET J et al.: Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control Study. Am. J. Respir. Crit. Care. Med. (2004) 170:836-844.
41. PLEWAKO H, ARVIDSSON M, PETRUSON K et al.: The effect of omalizumab on nasal allergic inflammation. J. Allergy. Clin. Immunol. (2002) 110:68-71.
42. NOGA O, HANK G, KUNKEL G: Immunological changes in allergic asthmatics following treatment with omalizumab. Int. Arch. Allergy. Immunol. (2003) 131:46-52.
43. DJUKANOVIC R, WILSON S, KRAFT M et al.: Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am. J. Respir. Crit. Care. Med. (2004) 170:583-593.
44. WARD C, PAIS M, BISH R et al.: Airway inflammation, basement membrane thickening and bronchial hyper responsiveness in asthma. Thorax (2002) 57:309-316.
45. WARD C, REID DW, ORSIDA BE et al.: Inter-relationships between airway inflammation, reticular basement membrane thickening and bronchial hyper-reactivity to methacholine in asthma: a systematic bronchoalveolar lavage and airway biopsy analysis. Clin. Exp. Allergy (2005) 35:1565-1571.
46. WENZEL SE: Asthma: defining of the persistent adult phenotypes. Lancet (2006) 368:804-813.
47. ARSHAD SH, HOLGATE S: The role of IgE in allergen-induced inflammation and the potential for intervention with a humanized monoclonal anti-IgE antibody. Clin. Exp. Allergy (2001) 31:1344-1351.
48. LANIER BQ: Unanswered questions and warnings involving anti-immunoglobulin E therapy based on 2 year observation of clinical experience. Allergy Asthma Proc. (2005) 26:435-439.
49. LANIER B: Unanswered clinical questions and speculation about the role of anti-Immunoglobulin E in atopic and nonatopic disease. Allergy Asthma Proc. (2006) 27:537-542.